Inquis Medical, Inc.

Based in Menlo Park, US, and founded in 2020 by co-founders and co-CEOs Vahid Saadat and Mojgan Saadat, Inquis Medical, Inc. operates as a provider of thrombectomy solutions intended to assist medical professionals in treating patients with vascular conditions, specifically addressing pulmonary embolism and deep vein thrombosis. In January 2026, Inquis Medical, Inc. raised USD 75 million in Series C funding.

The company’s primary offering is the AVENTUS Precision Thrombectomy System, an integrated solution intended for effective thrombectomy procedures targeting patients suffering from acute pulmonary embolism (PE) and deep vein thrombosis (DVT). This advanced system includes features such as navigation, aspiration, and blood return, along with sophisticated tissue sensing technology, which collectively improve the procedural efficiency and ease of use for healthcare professionals. The AVENTUS System is indicated for use specifically within the peripheral vasculature, allowing for a targeted approach in clot management. Additionally, the AVENTUS Clot Management System facilitates autologous blood transfusion, further improving patient care during these critical procedures.

The company's products are utilized primarily in the United States. The company generates revenue through direct sales of the AVENTUS Precision Thrombectomy System and its associated Clot Management System, catering to healthcare providers and institutions such as hospitals and surgical centers. The company will use the January 2026 funding to accelerate nationwide commercial expansion of its AVENTUS thrombectomy system and advance its next-generation product pipeline. The company will use the January 2026 funding to accelerate nationwide commercial expansion of its AVENTUS thrombectomy system and advance its next-generation product pipeline.